Key Points
- Outset Medical CEO Leslie Trigg sold 3,445 shares on May 15 at an average price of $3.70, worth about $12,746. The filing says the sale was to cover tax withholding tied to vested equity awards.
- After the transaction, Trigg still owned 98,874 shares, reducing her position by 3.37%. The sale was disclosed in an SEC filing.
- Outset Medical recently missed quarterly earnings estimates, reporting a loss of $0.83 per share on revenue of $27.86 million, while analysts currently rate the stock a consensus “Hold” with a $10 target price.
Outset Medical, Inc. (NASDAQ:OM - Get Free Report) CEO Leslie Trigg sold 3,445 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $3.70, for a total value of $12,746.50. Following the completion of the transaction, the chief executive officer directly owned 98,874 shares in the company, valued at $365,833.80. The trade was a 3.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Outset Medical Price Performance
Outset Medical stock opened at $3.86 on Wednesday. The firm has a market capitalization of $71.56 million, a P/E ratio of -0.93 and a beta of 1.92. Outset Medical, Inc. has a 1 year low of $3.00 and a 1 year high of $21.98. The business has a 50-day moving average of $3.94 and a 200-day moving average of $4.63. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87.
Outset Medical (NASDAQ:OM - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.79) by ($0.04). Outset Medical had a negative net margin of 63.65% and a negative return on equity of 56.13%. The firm had revenue of $27.86 million during the quarter, compared to analyst estimates of $28.90 million. On average, equities analysts anticipate that Outset Medical, Inc. will post -3.87 EPS for the current year.
Analyst Upgrades and Downgrades
OM has been the topic of several analyst reports. BTIG Research cut their target price on shares of Outset Medical from $17.00 to $15.00 and set a "buy" rating on the stock in a report on Thursday, February 12th. Weiss Ratings restated a "sell (e+)" rating on shares of Outset Medical in a research report on Friday, March 27th. TD Cowen reaffirmed a "buy" rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Wall Street Zen lowered Outset Medical from a "hold" rating to a "sell" rating in a report on Saturday, April 11th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $10.00.
Read Our Latest Stock Analysis on Outset Medical
Institutional Trading of Outset Medical
Hedge funds have recently bought and sold shares of the stock. BML Capital Management LLC boosted its holdings in shares of Outset Medical by 250.2% in the first quarter. BML Capital Management LLC now owns 1,902,201 shares of the company's stock valued at $7,304,000 after buying an additional 1,359,021 shares during the period. Millennium Management LLC raised its holdings in shares of Outset Medical by 165.8% during the third quarter. Millennium Management LLC now owns 421,409 shares of the company's stock worth $5,950,000 after acquiring an additional 262,874 shares during the period. Ensign Peak Advisors Inc raised its holdings in shares of Outset Medical by 71.8% during the fourth quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company's stock worth $2,078,000 after acquiring an additional 234,082 shares during the period. Renaissance Technologies LLC lifted its position in Outset Medical by 391.3% in the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company's stock valued at $853,000 after acquiring an additional 176,870 shares in the last quarter. Finally, Alyeska Investment Group L.P. boosted its stake in Outset Medical by 10.2% in the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company's stock worth $22,798,000 after purchasing an additional 150,000 shares during the period.
Outset Medical Company Profile
(
Get Free Report)
Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
